Biotest AG (BIESF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to Biotest AG (BIESF) stock?
Biotest AG (BIESF) no longer trades on public markets. The figures below are historical and are not a current quote.
P/E 48.06 means the share price is 48.06 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $1.60B is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Biotest AG (BIESF). Biotest AG, a subsidiary of Grifols, S.A., develops, manufactures, and sells biological medicines, primarily in hematology, clinical immunology, and intensive care medicine. Market cap: $1.60B, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for BIESF: BIESF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BIESF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 17 months ago — the most recent this company has published.
BIESF: 1/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Biotest AG (BIESF) Healthcare & Pipeline Overview
Biotest AG, a subsidiary of Grifols, S.A., operates in the biotechnology sector, developing and marketing biological medicines for hematology, clinical immunology, and intensive care. The company's focus on plasma-derived products and therapies for rare diseases positions it within a specialized segment of the global healthcare market, primarily serving Germany and international markets.
What Is the Investment Thesis for BIESF?
Biotest AG, as a subsidiary of Grifols, presents a focused investment opportunity within the specialized field of plasma-derived therapies. The company's established product portfolio in hematology, immunology, and intensive care provides a stable revenue base. Growth catalysts include the potential expansion of existing product lines and the introduction of new therapies. However, the company's negative profit margin of -7.1% and high P/E ratio of -36.18 indicate potential challenges in achieving profitability. The dividend yield is 0.13%.
Based on FMP financials and quantitative analysis
BIESF Key Highlights
Market capitalization of $1.60B reflects Biotest AG's current valuation within the biotechnology sector.
- Negative P/E ratio of -36.18 indicates that the company is currently not profitable.
- Gross margin of 20.1% shows the percentage of revenue exceeding the cost of goods sold.
- Dividend yield of 0.13% provides a small return for investors.
- Biotest AG operates as a subsidiary of Grifols, S.A., providing financial backing and strategic direction.
Who Are BIESF's Competitors?
BIESF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BITGF Biotage AB (publ) | $15.01 | 0.00% | $1.20B | — |
| CKDXF Opthea Limited | $0.01 | 0.00% | $13.7M | — |
| CMPUY CompuGroup Medical SE & Co. KGaA | $23.00 | -7.26% | $1.19B | — |
| DWRKF Drägerwerk AG & Co. KGaA | $543.70 | 0.00% | $1.75B | — |
| ETON Eton Pharmaceuticals, Inc. | $57.15 | -1.26% | $1.57B | 975-pillar |
| INVA Innoviva, Inc. | $20.56 | -0.29% | $1.52B | 945-pillar |
| VCEL Vericel Corporation | $37.50 | -0.98% | $1.92B | 915-pillar |
| LBRX LB Pharmaceuticals Inc | $46.25 | -2.98% | $1.33B | 675-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BIESF's Key Strengths?
Specialized expertise in plasma-derived therapies.
- Established product portfolio in hematology, immunology, and intensive care.
- Stringent regulatory approvals and compliance.
- Operates as a subsidiary of Grifols, S.A.
What Are BIESF's Weaknesses?
Negative profit margin.
- High P/E ratio.
- Dependence on plasma supply.
- Limited geographic diversification.
What Could Drive BIESF Stock Higher?
Clinical trial results for Trimodulin in community-acquired pneumonia and COVID-19.
- Regulatory approvals for new immunoglobulin therapies.
- Expansion into emerging markets in Asia and Latin America.
- Strategic partnerships and acquisitions to expand product portfolio.
- Advancements in plasma fractionation technology to improve efficiency.
What Are the Key Risks for BIESF?
Negative return on equity (-4.8%) — the business is not currently generating profit on shareholder capital.
- Rich valuation — a P/E of 48.06 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
- Competition from other biotechnology companies in the plasma-derived therapies market.
- Stringent regulatory requirements and compliance costs.
- Fluctuations in plasma supply and pricing.
- Patent expirations and generic competition.
- Negative profit margin and high P/E ratio.
What Are the Growth Opportunities for BIESF?
- Expansion of Trimodulin for Community-Acquired Pneumonia (CAP) and COVID-19: Trimodulin represents a significant growth opportunity for Biotest AG. Biotest's clinical trials and regulatory approvals will be critical milestones in capturing this market share. Success in these areas could significantly boost revenue and market position.
- Development of Novel Immunoglobulin Therapies: Biotest AG's focus on immunoglobulin therapies, such as Intratect and IgG Next Generation, presents a substantial growth opportunity. The global market for immunoglobulin therapies is expanding due to the increasing prevalence of immune deficiency disorders and autoimmune diseases. Biotest's research and development efforts in this area, coupled with successful clinical trials and regulatory approvals, could lead to the introduction of new and improved therapies, driving revenue growth.
- Geographic Expansion into Emerging Markets: Biotest AG has the opportunity to expand its geographic presence into emerging markets, particularly in Asia and Latin America. These regions are experiencing growing demand for plasma-derived therapies due to increasing healthcare expenditure and improving access to healthcare services. By establishing partnerships, distribution networks, and regulatory approvals in these markets, Biotest can tap into new revenue streams and diversify its geographic footprint.
- Strategic Partnerships and Acquisitions: Biotest AG can pursue strategic partnerships and acquisitions to expand its product portfolio, access new technologies, and strengthen its market position. Collaborations with other biotechnology companies, research institutions, and healthcare providers can accelerate the development and commercialization of new therapies. Acquisitions of complementary businesses can broaden Biotest's product offerings and geographic reach, creating synergies and enhancing shareholder value.
- Advancements in Plasma Fractionation Technology: Investing in advanced plasma fractionation technologies can improve the efficiency and yield of plasma-derived products, reducing production costs and increasing profitability. By adopting innovative technologies such as membrane chromatography and continuous processing, Biotest can optimize its manufacturing processes and enhance its competitive advantage. These advancements can also lead to the development of new and improved plasma-derived therapies, further driving revenue growth.
What Are BIESF's Competitive Advantages?
- Specialized expertise in plasma-derived therapies.
- Established product portfolio in hematology, immunology, and intensive care.
- Stringent regulatory approvals and compliance.
- Proprietary manufacturing processes and technologies.
What Does BIESF Do?
Biotest AG, founded in 1946 and headquartered in Dreieich, Germany, is a biotechnology company specializing in the development, manufacture, and sale of biological medicines. Originally known as Biotest Serum-Institut GmbH, the company changed its name in 1986. Its core business revolves around plasma-derived products used in hematology, clinical immunology, and intensive care medicine. Key products include treatments for hemophilia A and B (Haemoctin, Vihuma, and Haemonine), therapies for cytomegalovirus infections (Cytotect CP biotest), and prophylaxis against hepatitis B (Fovepta and Hepatect). Additionally, Biotest offers Intratect and IgG Next Generation for immune deficiencies and autoimmune diseases, Varitect for varicella zoster virus infections, and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides products like Albiomin and Biseko for blood volume restoration, Cofact for clotting factor deficiencies, Fibrinogen for congenital fibrinogen deficiency, Trimodulin for pneumonia and COVID-19, and Pentaglobin for bacterial infections. As of January 21, 2022, Biotest AG operates as a subsidiary of Grifols, S.A., a global healthcare company and a leading producer of plasma-derived medicines.
What Products and Services Does BIESF Offer?
- Develops biological medicines for hematology.
- Manufactures biological medicines for clinical immunology.
- Sells biological medicines for intensive care medicine.
- Offers treatments for hemophilia A and B.
- Provides therapies for cytomegalovirus infections.
- Offers prophylaxis against hepatitis B.
- Develops immunoglobulin therapies for immune deficiencies and autoimmune diseases.
- Provides products for blood volume restoration and clotting factor deficiencies.
How Does BIESF Make Money?
- Develops and manufactures plasma-derived products.
- Sells biological medicines directly to hospitals and healthcare providers.
- Generates revenue through product sales in Germany and internationally.
- Focuses on therapies for rare diseases and specialized medical conditions.
What Industry Does BIESF Operate In?
Biotest AG operates within the biotechnology industry, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market for plasma-derived therapies is driven by the increasing prevalence of chronic diseases, advancements in diagnostic technologies, and growing demand for specialized treatments. Biotest's focus on hematology, immunology, and intensive care positions it within specific segments of this market. Competitors include other biotechnology companies specializing in plasma-derived products and therapies for rare diseases. The industry is subject to regulatory oversight by agencies such as the European Medicines Agency (EMA) and other international regulatory bodies.
Who Are BIESF's Key Customers?
- Hospitals and clinics.
- Healthcare providers.
- Patients with hematological disorders.
- Patients with immunological disorders.
- Patients in intensive care units.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● Latest filing 529 days ago
- ● No analyst coverage
- ● Reported in EUR, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 4 snapshots
| 2026-08-23 | 48 |
| 2026-08-24 | 48 |
| 2026-08-25 | 48 |
| 2026-08-26 | 48 |
What changed?
The score has stayed at 48.
Over the same 3 days the stock moved +0.0%.
Biotest AG (BIESF) Valuation Context
Valued at $1.60B, BIESF is classified as a small-cap stock.
BIESF Revenue & Earnings Trend
In Q1 FY2025, BIESF generated $144.1M in top-line revenue, marking a sequential decrease of 39.0%. The company recorded a net loss of $24.8M, with diluted EPS of $-0.64. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, BIESF averaged $-0.19 in diluted EPS.
Company Profile
Biotest AG operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dreieich, DE. The company is led by CEO Jorg Schuttrumpf. BIESF has traded publicly since 2014.
Key Financial Metrics
Return on equity for Biotest AG stands at -4.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.93 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Biotest AG's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.15 places it in the grey zone, a middle ground that warrants monitoring.
BIESF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized expertise in plasma-derived therapies.
- Established product portfolio in hematology, immunology, and intensive care.
- Stringent regulatory approvals and compliance.
- Operates as a subsidiary of Grifols, S.A.
Bear Case
- Negative profit margin.
- High P/E ratio.
- Dependence on plasma supply.
- Limited geographic diversification.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 FY2025 | $144M | -$25M | -$0.64 |
| Q4 FY2024 | $236M | -$4M | -$0.11 |
| Q3 FY2024 | $175M | -$11M | -$0.29 |
| Q2 FY2024 | $182M | $11M | $0.28 |
Q1 FY2025 · filed 31 Mar 2025 · SEC EDGAR →
Based on FMP financials and quantitative analysis · Converted to USD from EUR at today's rate
BIESF Latest News
Leadership: Jorg Schuttrumpf
CEO
Jorg Schuttrumpf is the CEO of Biotest AG. As the CEO, he is responsible for the overall strategic direction and operational performance of the company, overseeing the development, manufacturing, and commercialization of biological medicines.
Track Record: Information regarding Jorg Schuttrumpf's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided context. His role involves guiding Biotest AG in its focus on plasma-derived products and therapies for rare diseases, as well as navigating the competitive landscape of the biotechnology industry.
BIESF OTC Market Information
The OTC Other tier, where BIESF trades, represents the lowest tier of the OTC market. Companies in this tier may not meet minimum financial standards and have limited reporting requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with unproven business models, early-stage ventures, or those facing financial distress. Investors should exercise caution and conduct thorough due diligence before investing in companies on this tier, as the risk of fraud and manipulation is higher.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry and the risk of making investment decisions based on incomplete or unreliable data.
- Lower liquidity can lead to price volatility and difficulties in buying or selling shares at desired prices.
- The OTC Other tier has a higher risk of fraud and manipulation compared to major exchanges.
- Biotest AG's financial performance and prospects may be more uncertain due to the limited availability of information.
- The company's compliance with regulatory requirements may be less stringent compared to companies listed on major exchanges.
- Verify the company's registration and legal status in Germany.
- Obtain and review the company's financial statements, if available, from German regulatory filings or other sources.
- Assess the company's business model, products, and market position.
- Evaluate the company's management team and corporate governance practices.
- Research the company's history and track record, including any past legal or regulatory issues.
- Understand the risks associated with investing in OTC stocks, including limited disclosure and liquidity.
- Consult with a financial advisor before making any investment decisions.
- Biotest AG is a subsidiary of Grifols, S.A., a reputable global healthcare company.
- The company has a long operating history, having been founded in 1946.
- Biotest AG develops and manufactures biological medicines for critical medical conditions.
- The company's products are subject to regulatory approvals and compliance.
- Biotest AG has a team of employees dedicated to research, development, and manufacturing.
Biotest AG Healthcare Stock: Key Questions Answered
What happened to Biotest AG (BIESF) stock?
Biotest AG (BIESF) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy BIESF shares?
No. BIESF stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for BIESF elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before BIESF stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Biotest AG. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Biotest AG do?
Biotest AG develops, manufactures, and sells biological medicines, primarily derived from plasma, for use in hematology, clinical immunology, and intensive care medicine.
What do analysts say about BIESF stock?
However, based on available financial data, Biotest AG has a market capitalization of $1.60B and a negative P/E ratio of -36.18, indicating that the company is currently not profitable. The gross margin is 20.1%, and the dividend yield is 0.13%. The company's beta is 0.00.
What are the main risks for BIESF?
The main risks for Biotest AG include competition from other biotechnology companies in the plasma-derived therapies market, stringent regulatory requirements and compliance costs, fluctuations in plasma supply and pricing, patent expirations and generic competition, and the company's current negative profit margin and high P/E ratio.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than data for exchange-listed stocks.